My opinion is they made it enticing enough for existing...

My opinion is they made it enticing enough for existing shareholders to average down their entry price. Remember 80% is held by Top 20.. So you would think they consulted with the Top 20 about averaging down their holdings through participating in an entitlemnt offer vs a heavily discounted cap raise. It gives everyone the opportunity to average down their entry price. Any stale shareholders get diluted heavily for not participating.



I am reading from the announcement: 2 shares for every 5 owned. PLUS one 12 month Option at same price and if you exercise that 12month opton within 3 months at same price(6c), you get an additional option. So initially $1.95M fully underwritten so you can assume done. And the possibility of another $1.95M in 3 months if people exercise their option and another $1.95M in 12 months if people exercise their first option for a second option.

It is of course based on continuous success BUT this is what a pharma speculative stock is about right? What I would love to know is how much they estimate the Peach Study will cost as they did mention some funding from somewhere in the US previously in one of their announcements. Also great result in this market to get it fully underwritten.


Do your own research. Read the prospectus in full. Not investment advice.